Analysis of gut microbiota and metabolomics in patients receiving tumor immunotherapy

The study of gut microbiota and metabolomics in patients with tumor Immunotherapy and immune-related adverse events

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062437

Enrollment

Unknown

Registered

2022-08-07

Start date

2022-07-30

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor immunotherapy efficacy and immune-related adverse events

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years, regardless of gender; 2. Patients diagnosed with lung cancer and receiving anti-PD-1 immunotherapy; 3. Subjects signed informed consent in writing and volunteered to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Vital signs unstable; 2. Patients with gastrointestinal obstruction, gastrointestinal bleeding, or septic shock; 3. Need long-term antibiotics treatment; 4. Pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
Fecal microbiome;Fecal metabolome;	—

Countries

China

Contacts

Public ContactTan Bei

Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College

tanbei0626@aliyun.com+86 010-69155017

Outcome results